Imagine your brain is like a complex electrical grid that gets a few short circuits after a virus attack. This work figures out exactly which 'wires' are damaged and why some people's grids are more fragile than others. By growing tiny brain models in a lab, they can test new medicines without risking a patient's health.
Healthcare systems are struggling to treat a rising number of patients with long-term cognitive and psychiatric issues following COVID-19. There is a critical lack of personalized diagnostic tools and targeted treatments for these neurological complications.
The project built comprehensive patient databases from two cohorts and developed robotic systems for scaling brain organoid production for drug testing.
If you are a drug discovery firm dealing with high failure rates in neuro-drug trials — this project developed laboratory-grown brain organoids that allow for testing repurposed drugs on authentic genetic backgrounds. This reduces risk before moving to human trials.
If you are an AI diagnostic software provider dealing with a lack of predictive markers for long-term illness — this project developed AI analytics to predict who is at risk for brain issues. This enables the creation of early-warning screening tools.
If you are a specialized neurology clinic dealing with a surge of post-COVID patients with memory loss — this project developed a way to characterize the phenotypic spectrum of NeuroCOVID. This allows for more personalized treatment trajectories for patients.
Based on available project data, there is no specific pricing or cost information provided for the resulting tools or models.
The project uses innovative robotics to scale brain organoid modelling, suggesting a move toward higher volume production than traditional manual methods.
Based on available project data, specific IP and licensing terms are not mentioned; however, the project involves 12 partners across 7 countries.
The project leverages two national health registries and three clinical cohorts to characterize the spectrum of NeuroCOVID.
The project runs from 2022-09-01 to 2027-08-31, indicating that final validations and translations are ongoing through 2027.
The consortium is heavily weighted toward research and academia, with 5 universities and 4 research institutions. However, there is a 17% industry presence consisting of 2 partners, including 1 SME, which suggests a bridge between basic science and commercial application. The coordination by a specialized center for neurodegenerative diseases ensures high technical expertise across 7 European and Middle Eastern countries.
Contact DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Contact us to explore licensing opportunities for the AI predictive models or organoid robotics.
